Home » Stocks » QLGN

Qualigen Therapeutics, Inc. (QLGN)

Stock Price: $3.29 USD -0.11 (-3.24%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $3.37 +0.08 (2.43%) Feb 26, 7:59 PM
Market Cap 87.87M
Revenue (ttm) 1.74M
Net Income (ttm) -28.80M
Shares Out 19.80M
EPS (ttm) -3.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $3.29
Previous Close $3.40
Change ($) -0.11
Change (%) -3.24%
Day's Open 3.35
Day's Range 0.45 - 3.45
Day's Volume 957,542
52-Week Range 0.17 - 9.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single inst...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 16, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a sing...

PRNewsWire - 2 months ago

CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formu...

PRNewsWire - 3 months ago

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter ...

PRNewsWire - 5 months ago

CARLSBAD, Calif., Aug. 31, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

PRNewsWire - 6 months ago

CARLSBAD, Calif., Aug. 28, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

Seeking Alpha - 6 months ago

Qualigen Therapeutics, Inc. (QLGN) CEO Michael Poirier on Q1 2021 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

CARLSBAD, Calif., Aug. 14, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

PRNewsWire - 6 months ago

CARLSBAD, Calif., Aug. 4, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

PRNewsWire - 6 months ago

CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

PRNewsWire - 7 months ago

CARLSBAD, Calif. , July 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc.

PRNewsWire - 7 months ago

CARLSBAD, Calif., July 13, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), announced that today Chief Executive Officer Michael Poirier has issue...

PRNewsWire - 7 months ago

CARLSBAD, Calif., July 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced the closing of its previously announced registered dir...

PRNewsWire - 7 months ago

CARLSBAD, Calif., July 8, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a singl...

PRNewsWire - 7 months ago

CARLSBAD, Calif., July 7, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has engaged Pro Football Hall of Fame and College Football ...

Benzinga - 8 months ago

Qualigen Therapeutics shares are trading higher on Wednesday, after the company signed an exclusive licensing agreement with the University of Louisville and it plans to develop its AS1411 for...

PRNewsWire - 8 months ago

CARLSBAD, Calif., June 10, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive license agreement with the Univ...

About QLGN

Qualigen, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and ... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Andrew Ritter
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
QLGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for QLGN stock is "Strong Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Strong Buy